{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:13:29Z","timestamp":1790421209559,"version":"4.1.0"},"reference-count":105,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA198846"],"award-info":[{"award-number":["U01CA198846"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy provides the best approach to reduce the high mortality of metastatic breast cancer (BC). We demonstrate a chemo-immunotherapy approach, which utilizes a liposomal carrier to simultaneously trigger immunogenic cell death (ICD) as well as interfere in the regionally overexpressed immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO-1) at the BC tumor site. The liposome was constructed by self-assembly of a phospholipid-conjugated prodrug, indoximod (IND), which inhibits the IDO-1 pathway, followed by the remote loading of the ICD-inducing chemo drug, doxorubicin (DOX). Intravenous injection of the encapsulated two-drug combination dramatically improved the pharmacokinetics and tumor drug concentrations of DOX and IND in an orthotopic 4T1 tumor model in syngeneic mice. Delivery of a threshold ICD stimulus resulted in the uptake of dying BC cells by dendritic cells, tumor antigen presentation and the activation\/recruitment of na\u0131\u0308ve T-cells. The subsequent activation of perforin- and IFN-\u03b3 releasing cytotoxic T-cells induced robust tumor cell killing at the primary as well as metastatic tumor sites. Immune phenotyping of the tumor tissues confirmed the recruitment of CD8+ cytotoxic T lymphocytes (CTLs), disappearance of Tregs, and an increase in CD8+\/FOXP3+ T-cell ratios. Not only does the DOX\/IND-Liposome provide a synergistic antitumor response that is superior to a DOX-only liposome, but it also demonstrated that the carrier could be effectively combined with PD-1 blocking antibodies to eradicate lung metastases. All considered, an innovative nano-enabled approach has been established to allow deliberate use of ICD to switch an immune deplete to an immune replete BC microenvironment, allowing further boosting of the response by coadministered IDO inhibitors or immune checkpoint blocking antibodies.<\/jats:p>","DOI":"10.1021\/acsnano.8b05189","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T12:05:04Z","timestamp":1539691504000},"page":"11041-11061","source":"Crossref","is-referenced-by-count":212,"title":["Breast Cancer Chemo-immunotherapy through Liposomal\nDelivery of an Immunogenic Cell Death Stimulus Plus Interference in\nthe IDO-1 Pathway"],"prefix":"10.1021","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-619X","authenticated-orcid":true,"given":"Jianqin","family":"Lu","sequence":"first","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-2838","authenticated-orcid":true,"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Pei","family":"Liao","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-2069","authenticated-orcid":true,"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ji","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-3938","authenticated-orcid":true,"given":"Huan","family":"Meng","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-4686","authenticated-orcid":true,"given":"Andre E.","family":"Nel","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]},{"name":"University of California, Los Angeles , , , ,","place":["Los Angeles, California, United States, 90095"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"2026090404245674000_cit1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/cncr.24760","article-title":"Annual\nReport to the Nation on the Status of Cancer, 1975\u20132006, Featuring\nColorectal Cancer Trends and Impact of Interventions (risk factors,\nscreening, and treatment) to Reduce Future Rates","volume":"116","author":"Edwards","year":"2010","journal-title":"Cancer"},{"key":"2026090404245674000_cit2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/jwh.2013.4517","article-title":"Does Removal of the Primary Tumor in Metastatic Breast\nCancer Improve Survival?","volume":"23","author":"Rashid","year":"2014","journal-title":"J. Womens Health"},{"key":"2026090404245674000_cit3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The Blockade\nof Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"2026090404245674000_cit4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2026090404245674000_cit5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel Cancer Immunotherapy\nAgents with Survival Benefit: Recent Successes and Next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"2026090404245674000_cit6","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for Breast Cancer:\nWhat Are We Missing?","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2026090404245674000_cit7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the Cancer Microenvironment\nand Their Relevance in Cancer Immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"2026090404245674000_cit8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The Landscape of Cancer Genes and Mutational Processes\nin Breast Cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"2026090404245674000_cit9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/2326-6066.CIR-16-0264","article-title":"Breast Cancer Neoantigens\nCan Induce CD8(+) T-Cell Responses and Antitumor Immunity","volume":"5","author":"Zhang","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"2026090404245674000_cit10","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1158\/0008-5472.CAN-16-0170","article-title":"Burden of Nonsynonymous Mutations Among TCGA Cancers\nand Candidate Immune Checkpoint Inhibitor Responses","volume":"76","author":"Colli","year":"2016","journal-title":"Cancer Res."},{"key":"2026090404245674000_cit11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging Concepts for Immune Checkpoint\nBlockade-Based Combination Therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer\nCell"},{"key":"2026090404245674000_cit12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of Tumor-Infiltrating\nLymphocytes in Breast Cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med."},{"key":"2026090404245674000_cit13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/biomedicines6010020","article-title":"Immune Landscape of Breast Cancers","volume":"6","author":"Nagarajan","year":"2018","journal-title":"Biomedicines"},{"key":"2026090404245674000_cit14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-Associated Lymphocytes as an\nIndependent Predictor of Response to Neoadjuvant Chemotherapy in Breast\nCancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2026090404245674000_cit15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.3944","article-title":"Natural and\nTherapy-Induced Immunosurveillance in Breast Cancer","volume":"21","author":"Kroemer","year":"2015","journal-title":"Nat. Med."},{"key":"2026090404245674000_cit16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and Predictive\nValue of Tumor-infiltrating Lymphocytes in a Phase III Randomized\nAdjuvant Breast Cancer Trial in Node-positive Breast Cancer Comparing\nthe Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy:\nBIG 02\u201398","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2026090404245674000_cit17","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-07-4491","article-title":"Pathologic\nComplete Response to Neoadjuvant Chemotherapy of Breast Carcinoma\nIs Associated with the Disappearance of Tumor-infiltrating Foxp3+\nRegulatory T Cells","volume":"14","author":"Ladoire","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2026090404245674000_cit18","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An Immunosurveillance Mechanism Controls Cancer Cell Ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"2026090404245674000_cit19","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-Regulation of PD-L1, IDO, and\nT(regs) in the Melanoma Tumor Microenvironment Is Driven by CD8(+)\nT cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2026090404245674000_cit20","doi-asserted-by":"publisher","first-page":"S5-07","DOI":"10.1158\/1538-7445.SABCS15-S5-07","article-title":"Abstract S5\u201307: Preliminary\nEfficacy and Safety of Pembrolizumab (MK-3475) in Patients with PD-L1\u2013positive,\nEstrogen Receptor-Positive (ER+)\/HER2-Negative Advanced Breast Cancer\nEnrolled in KEYNOTE-028","volume":"76","author":"Rugo","year":"2016","journal-title":"Cancer Res."},{"key":"2026090404245674000_cit21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death\nin Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"2026090404245674000_cit22","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-Enabled Pancreas Cancer Immunotherapy\nUsing Immunogenic Cell Death and Reversing Immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"2026090404245674000_cit23","doi-asserted-by":"publisher","first-page":"e1008866","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: Immunogenic Cell Death Inducers for Anticancer\nChemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026090404245674000_cit24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1074-7613(01)00111-X","article-title":"CD91 Is\na Common Receptor for Heat Shock Proteins Gp96, Hsp90, Hsp70, and\nCalreticulin","volume":"14","author":"Basu","year":"2001","journal-title":"Immunity"},{"key":"2026090404245674000_cit25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0092-8674(03)00758-X","article-title":"By Binding SIRPalpha or Calreticulin\/CD91,\nLung Collectins Act as Dual Function Surveillance Molecules to Suppress\nor Enhance Inflammation","volume":"115","author":"Gardai","year":"2003","journal-title":"Cell"},{"key":"2026090404245674000_cit26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin Exposure Dictates the\nImmunogenicity of Cancer Cell Death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"2026090404245674000_cit27","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic Tumor Cell Death for Optimal Anticancer\nTherapy: the Calreticulin Exposure Pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"2026090404245674000_cit28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like Receptor 4-Dependent Contribution of the Immune System\nto Anticancer Chemotherapy and Radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"2026090404245674000_cit29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent Immunogenicity\nof Doxorubicin-Induced Tumor Cell Death","volume":"202","author":"Casares","year":"2005","journal-title":"J.\nExp. Med."},{"key":"2026090404245674000_cit30","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human Tumor Cells Killed by Anthracyclines\nInduce a Tumor-specific Immune Response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer\nRes."},{"key":"2026090404245674000_cit31","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","article-title":"Autophagy-Dependent\nAnticancer Immune Responses Induced by Chemotherapeutic Agents in\nMice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science"},{"key":"2026090404245674000_cit32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive\nNetworks in the Tumour Environment and Their Therapeutic Relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"2026090404245674000_cit33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00262-013-1393-y","article-title":"Analysis of Indoleamine\n2\u20133 Dioxygenase (IDO1) Expression in Breast Cancer Tissue by\nImmunohistochemistry","volume":"62","author":"Soliman","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"2026090404245674000_cit34","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.3816\/CBC.2009.s.007","article-title":"First-Line Chemotherapy for Metastatic Breast Cancer","volume":"9","author":"Telli","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"2026090404245674000_cit35","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1021\/mp500389v","article-title":"Targeted Delivery of Doxorubicin\nby Folic Acid-decorated Dual Functional Nanocarrier","volume":"11","author":"Lu","year":"2014","journal-title":"Mol. Pharmaceutics"},{"key":"2026090404245674000_cit36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jconrel.2014.10.016","article-title":"An Improved D-Alpha-Tocopherol-Based Nanocarrier for\nTargeted Delivery of Doxorubicin with Reversal of Multidrug Resistance","volume":"196","author":"Lu","year":"2014","journal-title":"J. Controlled Release"},{"key":"2026090404245674000_cit37","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1021\/bm501339j","article-title":"Targeted Delivery of\nAnticancer Agents via a Dual Function Nanocarrier\nwith an Interfacial Drug-Interactive Motif","volume":"15","author":"Zhang","year":"2014","journal-title":"Biomacromolecules"},{"key":"2026090404245674000_cit38","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated Liposomal Doxorubicin: a Review of Its Use\nin Metastatic Breast Cancer, Ovarian Cancer, Multiple Myeloma and\nAIDS-related Kaposi\u2019s Sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"2026090404245674000_cit39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of Pegylated Liposomal\nDoxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"2026090404245674000_cit40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2014.05.019","article-title":"Improving the Distribution\nof Doxil\u00ae in the Tumor Matrix by Depletion of Tumor\nHyaluronan","volume":"191","author":"Kohli","year":"2014","journal-title":"J. Controlled Release"},{"key":"2026090404245674000_cit41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fimmu.2014.00673","article-title":"Cancer Immunotherapy\nby Targeting IDO1\/TDO and Their Downstream Effectors","volume":"5","author":"Platten","year":"2015","journal-title":"Front. Immunol."},{"key":"2026090404245674000_cit101","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO Expression in Human\nCancer Is Sustained by an Autocrine Signaling Loop Involving IL-6,\nSTAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"2026090404245674000_cit43","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1\nInhibitors: From Bench to Bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"2026090404245674000_cit44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade\nTherapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"2026090404245674000_cit45","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus Guidelines for the Detection of Immunogenic Cell Death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026090404245674000_cit46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","article-title":"Drug Delivery Approaches in Addressing\nClinical Pharmacology-Related Issues: Opportunities and Challenges","volume":"17","author":"Wen","year":"2015","journal-title":"AAPS J."},{"key":"2026090404245674000_cit47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/17435889.3.1.125","article-title":"Electron Tomography in Nanoparticle\nImaging and Analysis","volume":"3","author":"Lengyel","year":"2008","journal-title":"Nanomedicine (London,\nU. K.)"},{"key":"2026090404245674000_cit48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-014-3118-0","article-title":"An Improved Syngeneic Orthotopic Murine Model of Human\nBreast Cancer Progression","volume":"147","author":"Rashid","year":"2014","journal-title":"Breast Cancer Res.\nTreat."},{"key":"2026090404245674000_cit49","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a Highly Active Nanoliposomal Irinotecan\nUsing A Novel Intraliposomal Stabilization Strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"2026090404245674000_cit50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated\nLiposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer","volume":"10","author":"Rose","year":"2005","journal-title":"Oncologist"},{"key":"2026090404245674000_cit51","first-page":"411","article-title":"Reflections on Immune Checkpoint Inhibition in Non-Small\nCell Lung Cancer","volume":"3","author":"Leventakos","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"2026090404245674000_cit52","doi-asserted-by":"publisher","first-page":"e1373237","DOI":"10.1080\/2162402X.2017.1373237","article-title":"Trial Watch:\nImmune Checkpoint Blockers for Cancer Therapy","volume":"6","author":"Vanpouille-Box","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026090404245674000_cit53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-Infiltrating\nLymphocytes and Response to Neoadjuvant Chemotherapy with or Without\nCarboplatin in Human Epidermal Growth Factor Receptor 2-Positive and\nTriple-Negative Primary Breast Cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin.\nOncol."},{"key":"2026090404245674000_cit54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11605-017-3566-z","article-title":"Neoadjuvant\nChemotherapy Improves Survival in Patients with Clinical T4b Colon\nCancer","volume":"22","author":"Dehal","year":"2018","journal-title":"J. Gastrointest. Surg.: official journal\nof the Society for Surgery of the Alimentary Tract"},{"key":"2026090404245674000_cit55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.kjms.2012.08.034","article-title":"Neoadjuvant Chemotherapy\nImproves Survival Rate in Advanced Urothelial Carcinoma","volume":"29","author":"Tsai","year":"2013","journal-title":"Kaohsiung J. Med. Sci."},{"key":"2026090404245674000_cit56","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic Death of Colon Cancer Cells Treated with\nOxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"2026090404245674000_cit57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-Mobility Group Box 1 Protein (HMGB1): Nuclear\nWeapon in the Immune Arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"2026090404245674000_cit58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular Mechanisms\nof ATP Secretion During Immunogenic Cell Death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Differ."},{"key":"2026090404245674000_cit59","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.4161\/auto.25873","article-title":"Autophagy-Dependent ATP Release from Dying Cells via Lysosomal Exocytosis","volume":"9","author":"Wang","year":"2013","journal-title":"Autophagy"},{"key":"2026090404245674000_cit60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fimmu.2012.00414","article-title":"ATP Release and Purinergic Signaling\nin NLRP3 Inflammasome Activation","volume":"3","author":"Gombault","year":"2013","journal-title":"Front. Immunol."},{"key":"2026090404245674000_cit61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and Regulation of the\nInflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2026090404245674000_cit62","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1073\/pnas.0709684105","article-title":"ATP Is Released by Monocytes Stimulated with Pathogen-sensing\nReceptor Ligands and Induces IL-1beta and IL-18 Secretion in an Autocrine\nWay","volume":"105","author":"Piccini","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090404245674000_cit63","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1038\/cddis.2012.144","article-title":"ATP Release and Purinergic Signaling: a Common Pathway\nfor Particle-Mediated Inflammasome Activation","volume":"3","author":"Riteau","year":"2012","journal-title":"Cell Death Dis."},{"key":"2026090404245674000_cit64","doi-asserted-by":"publisher","first-page":"12499","DOI":"10.1038\/ncomms12499","article-title":"Core-Shell Nanoscale Coordination\nPolymers Combine Chemotherapy and Photodynamic Therapy to Potentiate\nCheckpoint Blockade Cancer Immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat.\nCommun."},{"key":"2026090404245674000_cit65","doi-asserted-by":"publisher","first-page":"e968434","DOI":"10.4161\/21624011.2014.968434","article-title":"Physical Modalities Inducing Immunogenic Tumor Cell\nDeath for Cancer Immunotherapy","volume":"3","author":"Adkins","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026090404245674000_cit66","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0169-409X(96)00476-0","article-title":"Long-Circulating Liposomes for Drug Delivery in Cancer\nTherapy: a Review of Biodistribution Studies in Tumor-Bearing Animals","volume":"24","author":"Gabizon","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026090404245674000_cit67","doi-asserted-by":"publisher","first-page":"e82331","DOI":"10.1371\/journal.pone.0082331","article-title":"Pharmacokinetics,\nBrain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione\nPegylated Liposomal Doxorubicin (2B3\u2013101)","volume":"9","author":"Gaillard","year":"2014","journal-title":"PLoS One"},{"key":"2026090404245674000_cit68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated Liposomal Doxorubicin: Proof of Principle\nUsing Preclinical Animal Models and Pharmacokinetic Studies","volume":"31","author":"Vail","year":"2004","journal-title":"Semin. Oncol."},{"key":"2026090404245674000_cit69","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/aps.2017.44","article-title":"Programmable Co-delivery\nof the Immune Checkpoint Inhibitor NLG919 and Chemotherapeutic Doxorubicin via a Redox-Responsive Immunostimulatory Polymeric Prodrug\nCarrier","volume":"38","author":"Sun","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"2026090404245674000_cit70","unstructured":"National Library of Medicine (US). Identifier NCT02048709, Indoleamine\n2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors. Jan 29, 2014\u2013Feb 6, 2017. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02048709."},{"key":"2026090404245674000_cit71","unstructured":"National Library of Medicine (US). Identifier NCT02471846, A Study\nof GDC-0919 and Atezolizumab Combination Treatment in Participants\nwith Locally Advanced or Metastatic Solid Tumors.\nJune 15, 2015\u2013July 30, 2018. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02471846."},{"key":"2026090404245674000_cit72","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human Phase I Study of the\nOral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360)\nin Patients with Advanced Solid Malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2026090404245674000_cit73","doi-asserted-by":"publisher","first-page":"e3794","DOI":"10.1002\/bmc.3794","article-title":"Determination of Epacadostat, a Novel\nIDO1 Inhibitor in Mouse Plasma by LC-MS\/MS and Its Application to\na Pharmacokinetic Study in Mice","volume":"31","author":"Dhiman","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"2026090404245674000_cit74","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360\n(Epacadostat), a Highly Potent and Selective Indoleamine-2,3-Dioxygenase\n1 (IDO1) Inhibitor for Immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS\nMed. Chem. Lett."},{"key":"2026090404245674000_cit75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the\nTreatment of PD-L1 Positive Advanced or Metastatic Non-Small Cell\nLung Cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2026090404245674000_cit76","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer\nImmunotherapy: Opportunities and Challenges in the Rapidly Evolving\nClinical Landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"2026090404245674000_cit77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.20892\/j.issn.2095-3941.2016.0015","article-title":"Immuno-Oncology\nCombinations: Raising the Tail of the Survival Curve","volume":"13","author":"Harris","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"2026090404245674000_cit78","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","article-title":"Predictors of Responses to Immune Checkpoint\nBlockade in Advanced Melanoma","volume":"8","author":"Jacquelot","year":"2017","journal-title":"Nat. Commun."},{"key":"2026090404245674000_cit79","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11864-014-0305-5","article-title":"Immune Checkpoint Inhibitors in NSCLC","volume":"15","author":"Johnson","year":"2014","journal-title":"Curr. Treat. Options Oncol"},{"key":"2026090404245674000_cit80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale\nfor Combination of Therapeutic Antibodies Targeting Tumor Cells and\nImmune Checkpoint Receptors: Harnessing Innate and Adaptive Immunity\nThrough LgG1 Isotype Immune Effector Stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"2026090404245674000_cit81","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive,\nand Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2026090404245674000_cit82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2016.05.006","article-title":"Monitoring Immune Responses\nin the Tumor Microenvironment","volume":"41","author":"Wargo","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"2026090404245674000_cit83","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/14712598.2017.1309387","article-title":"Are Tumor-Infiltrating Lymphocytes\nProtagonists or Background Actors in Patient Selection for Cancer\nImmunotherapy?","volume":"17","author":"Zito Marino","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"2026090404245674000_cit84","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer\nImmunoediting: from Immunosurveillance to Tumor Escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"2026090404245674000_cit85","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific\nMutant Antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"2026090404245674000_cit86","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer Immunology. Mutational Landscape Determines\nSensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2026090404245674000_cit87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2051013614525375","article-title":"MHC Class I Antigen Presentation and Implications for\nDeveloping a New Generation of Therapeutic Vaccines","volume":"2","author":"Comber","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"2026090404245674000_cit88","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-Cell-Based Therapeutic Cancer Vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"2026090404245674000_cit89","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal\nNeoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune\nCheckpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2026090404245674000_cit90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08097","article-title":"Enhancing CD8 T-Cell\nMemory by Modulating Fatty Acid Metabolism","volume":"460","author":"Pearce","year":"2009","journal-title":"Nature"},{"key":"2026090404245674000_cit91","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2026090404245674000_cit92","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4\nCan Function as a Negative Regulator of T Cell Activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"2026090404245674000_cit93","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development\nof Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding\nan ITIM Motif-Carrying Immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"2026090404245674000_cit94","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune Dilated\nCardiomyopathy in PD-1 Receptor-Deficient Mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"2026090404245674000_cit95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 Costimulatory Pathways\nin Autoimmunity and Transplantation","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu. Rev.\nImmunol."},{"key":"2026090404245674000_cit96","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1\u2013\/\u2013 Mice as an Efficient\nAnimal Model of Type I Diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"key":"2026090404245674000_cit97","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and Tolerogenic\nCell Death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"2026090404245674000_cit98","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nri.2016.153","article-title":"Programmed Cell Death and the Immune System","volume":"17","author":"Nagata","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"2026090404245674000_cit99","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2407-12-120","article-title":"A Mouse Model for Triple-Negative\nBreast Cancer Tumor-Initiating Cells (TNBC-TICs) Exhibits Similar\nAggressive Phenotype to the Human Disease","volume":"12","author":"Kaur","year":"2012","journal-title":"BMC\nCancer"},{"key":"2026090404245674000_cit100","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO Inhibits a Tryptophan Sufficiency Signal that Stimulates\nmTOR: a Novel IDO Effector Pathway Targeted by D-1-Methyl-Tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"key":"2026090404245674000_cit102","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.biomaterials.2012.10.073","article-title":"PEG-Derivatized\nEmbelin as a Nanomicellar Carrier for Delivery of Paclitaxel to Breast\nand Prostate Cancers","volume":"34","author":"Lu","year":"2013","journal-title":"Biomaterials"},{"key":"2026090404245674000_cit103","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1021\/bc3000468","article-title":"PEG-Derivatized Embelin as a Dual\nFunctional Carrier for the Delivery of Paclitaxel","volume":"23","author":"Huang","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"2026090404245674000_cit104","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1002\/bmc.3863","article-title":"LC-MS\/MS Method Development\nfor Quantification of Doxorubicin and Its Metabolite 13-Hydroxy Doxorubicin\nin Mice Biological Matrices: Application to a Pharmaco-Delivery Study","volume":"31","author":"Mazzucchelli","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"2026090404245674000_cit105","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00280-004-0900-4","article-title":"Pharmacokinetics of Low-Dose Doxorubicin\nand Metabolites in Patients with AIDS-Related Kaposi Sarcoma","volume":"55","author":"Joerger","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026090404245674000_cit106","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/annonc\/mdq230","article-title":"Pharmacokinetics and\nPharmacodynamics of Docetaxel with or Without Ketoconazole Modulation\nin Chemonaive Breast Cancer Patients","volume":"21","author":"Lim","year":"2010","journal-title":"Ann. Oncol."}],"updated-by":[{"DOI":"10.1021\/acsnano.0c08653","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"record-id":"28843"}],"container-title":["ACS Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsnano.8b05189","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/12\/11\/11041\/67346778\/acsnano.8b05189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/12\/11\/11041\/67346778\/acsnano.8b05189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:49:44Z","timestamp":1788511784000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ancac3\/article\/12\/11\/11041\/747260\/Breast-Cancer-Chemo-immunotherapy-through"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":105,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,10,16]]},"published-print":{"date-parts":[[2018,11,27]]}},"URL":"https:\/\/doi.org\/10.1021\/acsnano.8b05189","relation":{},"ISSN":["1936-0851","1936-086X"],"issn-type":[{"value":"1936-0851","type":"print"},{"value":"1936-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]}}}